This is an early access version
,
Sarajevo School of Science and Technology, Medical Faculty, Sarajevo, Bosnia and Herzegovina , Clinical Center University of Sarajevo , Sarajevo , Bosnia and Herzegovina
Clinical Center University of Sarajevo , Sarajevo , Bosnia and Herzegovina
Clinical Center University of Sarajevo , Sarajevo , Bosnia and Herzegovina
Clinical Center University of Sarajevo , Sarajevo , Bosnia and Herzegovina
Clinical Center University of Sarajevo , Sarajevo , Bosnia and Herzegovina
Clinical Center University of Sarajevo , Sarajevo , Bosnia and Herzegovina
Aim To investigate the relationship between postoperative serum thyroglobulin level and outcome of therapy with I-131 of follicular thyroid cancer.
Methods A total of 106 patients with follicular thyroid cancer who were being treated and monitored at the Clinic for Nuclear Medicine at Clinical Center of the University of Sarajevo were included. The inclusion criteria were: surgery of total thyroidectomy, histopathological diagnosis of follicular thyroid cancer, and applied therapy with radioactive iodine. Exclusion criteria were patients with incomplete data, who were not treated with radioidine treatment, or had a different histopathological diagnosis. Postoperative serum thyroglobulin levels were correlated with results of whole body scintigraphies after 12 months (first diagnostic scintigraphy) and whole body scintigraphies after 24 months (second diagnostic scintigraphy).
Results The higher frequency of recurrent disease in patients with elevated level of thyroglobulin was found compared to patients with lower postoperative thyroglobulin level. Elevated level of postoperative thyroglobulin correlated with positive scintigraphy findings, i.e., with the occurrence of recurrence and/or metastases in patients with follicular cancer. The cut-off level of postoperative thyroglobulin for recurrence and/or metastasis, i.e. for failure of ablative therapy with I-131, was >12.6 ng/mL.
Conclusion Our study showed that level of postoperative thyroglobulin is an important prognostic factor for the outcome of radiodine therapy of follicular thyroid cancer and should be taken into account in deciding on therapy in this type of cancer in everyday practice
Keywords: prognosis, radioiodine, thyroid neoplasm, recurrence
Conceptualization, S.A., Š.C. and T.C.; Data curation, S.A., A.D. and E.Đ.; Investigation, S.A. and Š.C.; Methodology, S.A., Š.C., A.D. and E.Đ.; Validation, S.A., Š.C., A.B. and T.C.; Writing – original draft, S.A.; Writing – review & editing, S.A., A.B. and T.C.; Supervision, Š.C., A.B. and T.C.; Formal Analysis, A.D. and E.Đ. All authors have read and agreed to the published version of the manuscript.
No specific funding was received for this study.
Authors retain copyright. This work is licensed under a Creative Commons Attribution 4.0 International License. 
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.